Patents Assigned to Eli Lilly and Company
  • Patent number: 11028074
    Abstract: The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 8, 2021
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Maria Cristina Garcia Paredes, Lawrence Joseph Heinz, II, Jennifer Marie Howell, Frank George Njoroge, Yan Wang, Genshi Zhao
  • Patent number: 11008336
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Eli Lilly and Company
    Inventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
  • Patent number: 11001596
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 11, 2021
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Patric James Hahn, Zoran Rankovic
  • Patent number: 10987472
    Abstract: The present disclosure relates to a dose detection system for use in combination with a medication delivery device. In one aspect, the system includes a module body adapted to be removably attached to the actuator of a medication delivery device, and a plurality of magnetic sensing elements attached to said module body. The magnetic sensing elements can be spaced apart from one another to define a ring pattern. The system detects the amount of rotation of a magnetic ring of said one or more dipoles of a medication delivery device relative to the magnetic sensing elements during dose delivery when the module is attached to the device.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: April 27, 2021
    Assignee: Eli Lilly and Company
    Inventors: Roy Howard Byerly, Rossano Claudio Massari, Davide Paccioretti, Russell Wayne Perkins
  • Patent number: 10988529
    Abstract: A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 27, 2021
    Assignee: Eli Lilly and Company
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry
  • Patent number: 10987471
    Abstract: An injection device having a drive member with first and second gear patterns that are fixed relative to each other. The drive member is rotatable and translatable in first and second opposing axial directions. A plunger expels medicament from a cartridge when it is translated in an advancing direction. A dosage indicator indicates a set dosage. A first gearing arrangement operably couples the first gear pattern with the plunger wherein rotation of the drive member in a first direction translates the drive member in a first axial direction without movement of the plunger and translation of the drive member in the opposite axial direction drives the plunger in the advancing direction. A second gearing arrangement operably couples the second gear pattern with the dosage indicator and moves the dosage indicator to indicate an increase in the set dosage when the drive member is translated in the first axial direction.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 27, 2021
    Assignee: Eli Lilly and Company
    Inventor: Scott Matthew Stiffler
  • Patent number: 10968214
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 6, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, David Andrew Coates, Ryan James Linder, Sheng-Bin Peng, Mohammad Sadegh Zia-Ebrahimi
  • Patent number: 10954292
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: March 23, 2021
    Assignee: Eli Lilly and Company
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Patent number: 10934280
    Abstract: The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease, and/or the cardiovascular disease associated with chronic kidney disease.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: March 2, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Robert Fales, Jeffrey Allen Peterson, Jeffrey Michael Schkeryantz, Quanrong ' Shen, Matthew John Valli, John Rowley Wetterau, II, Dariusz Stanislaw Wodka, Yanping Xu
  • Patent number: 10925931
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 23, 2021
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • Patent number: 10919959
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Patent number: 10913799
    Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, Victor H Obungu
  • Patent number: 10913793
    Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: February 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
  • Patent number: 10906983
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and is useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 2, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
  • Patent number: D914199
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: March 23, 2021
    Assignee: Eli Lilly and Company
    Inventor: Kathryn Amanda Levy
  • Patent number: D914710
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: March 30, 2021
    Assignee: Eli Lilly and Company
    Inventors: Christopher Todd Collins, Rebecca Morgan Eley, Kathryn Ann Kollett, Joshua David Littlejohn
  • Patent number: D920349
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 25, 2021
    Assignee: Eli Lilly and Company
    Inventors: Korey Allen Clements, Shannon Danielle Lebryk
  • Patent number: D920350
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 25, 2021
    Assignee: Eli Lilly and Company
    Inventors: Korey Allen Clements, Shannon Danielle Lebryk
  • Patent number: D920362
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 25, 2021
    Assignee: Eli Lilly and Company
    Inventor: Korey Allen Clements
  • Patent number: D920363
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 25, 2021
    Assignee: Eli Lilly and Company
    Inventor: Korey Allen Clements